Reporter: Sarah Maxwell BARCELONA—Pembrolizumab did not significantly improve overall survival (OS) or progression free survival (PFS) compared with...
Audio Journal of Oncology Podcast Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib Play Episode Pause Episode Mute/Unmute...